UnitedHealth Group (UNH), the largest health insurer in the United States, has recently navigated a challenging landscape marked by disappointing second-quarter earnings and a revised, lower outlook for the year. Despite these hurdles, analysts predict a rebound in the company’s performance by 2026, driven by strategic initiatives aimed at cost reduction, pricing enhancements, and operational efficiency. This projected recovery presents an opportune moment for investors to consider UNH stock, particularly through exchange-traded funds (ETFs) that provide a diversified portfolio without the inherent risks of direct stock ownership.
For investors interested in gaining exposure to UNH, two notable ETFs are the Simplify Health Care ETF (PINK) and the T. Rowe Price Health Care ETF (TMED).
The Simplify Health Care ETF (PINK) is actively managed and focuses on innovative U.S. healthcare firms across various sectors such as biotechnology, medical technology, and gene therapy. The ETF aims for long-term capital appreciation and includes UNH stock, which makes up approximately 6.3% of its total holdings. Additionally, it features prominent companies like AbbVie, Eli Lilly, and CVS Health. Currently, the PINK ETF manages assets worth $156.06 million and has an expense ratio of 0.5%. Over the past three months, it has delivered a 10% return. Analyst sentiment surrounding the ETF is robust, as indicated by a Strong Buy consensus rating on TipRanks, supported by 55 Buys and 10 Holds. The current price target of $38.25 indicates a potential upside of 16.85%.
On the other hand, the T. Rowe Price Health Care ETF (TMED) also offers an actively managed investment strategy, targeting long-term growth across the healthcare spectrum, including pharmaceuticals, biotechnology, medical devices, and healthcare services. UNH stock constitutes about 7.96% of the TMED holdings, alongside other major stocks such as AbbVie, Abbott, and Intuitive Surgical. With an asset management total of $13.33 million and an expense ratio of 0.44%, the TMED ETF has recorded a slightly higher return of 10.8% over the last three months. Wall Street analysts have given the TMED ETF a Strong Buy consensus rating, with 89 of the 100 holdings classified as Buys, 10 as Holds, and only one as a Sell. The average price target for the TMED ETF stands at $34.24, suggesting a potential upside of 22.3%.
In summary, both the PINK and TMED ETFs present attractive options for investors looking to gain indirect exposure to UnitedHealth stock, mitigating risks associated with direct investment. With their focus on liquidity and transparency, these ETFs enable investors to strategically participate in the healthcare market, particularly as expectations for UnitedHealth’s recovery grow.
